ERBB2 and breast neoplasm: The decrease or loss of HER2 following trastuzumab treatment has previously been reported in a subset of patients in the clinical settings, where HER2 status was evaluated in paired pre-treatment and post-treatment breast tumours using either immunohistochemistry (IHC) or fluorescence in situ hybridisation (FISH) [85–89].